Kroemer, Guido http://orcid.org/0000-0002-9334-4405
Galassi, Claudia
Zitvogel, Laurence
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Article History
Received: 14 October 2021
Accepted: 7 January 2022
First Online: 10 February 2022
Competing interests
: G. K. has held research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Samsara, Sanofi, Sotio, Vascage and Vasculox/Tiom, is on the Board of Directors of the Bristol Myers Squibb Foundation France, and is a scientific co-founder of everImmune, Samsara Therapeutics and Therafast Bio. L. Z. has held research contracts with GlaxoSmythKline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Merus, Transgene, Tusk and Roche, is on the board of directors of Transgene and is a co-founder of everImmune. L. G. has held research contracts with Lytix Biopharma and Phosplatin, and has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, Sotio, The Longevity Labs, Inzen and the Luke Heller TECPR2 Foundation. All other authors have no conflicts to declare.
Free to read: This content has been made available to all.